-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WUi7qLp+ZPIVG9AvoTjTcnsGosld3v+z/5LaeOGQtFsNDlxTSih53XZ22jYH2y5m
 07RWb9r0MeT9kFhqX5Pz3w==

<SEC-DOCUMENT>0000922423-05-000714.txt : 20050426
<SEC-HEADER>0000922423-05-000714.hdr.sgml : 20050426
<ACCEPTANCE-DATETIME>20050426170934
ACCESSION NUMBER:		0000922423-05-000714
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050426
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050426
DATE AS OF CHANGE:		20050426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEPHROS INC
		CENTRAL INDEX KEY:			0001196298
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133971809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32288
		FILM NUMBER:		05773858

	BUSINESS ADDRESS:	
		STREET 1:		3960 BROADWAY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10032
		BUSINESS PHONE:		2127815113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kl00464_8k.txt
<DESCRIPTION>FORM 8-K CURRENT REPORT
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                           __________________________


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported) April 26, 2005 (April 26, 2005)
                                                  ------------------------------



                                  Nephros, Inc.
                                  -------------
               (Exact Name of Registrant as Specified in Charter)

                        Commission File Number: 001-32288
                                                ---------

           Delaware                                         13-3971809
           --------                                         ----------
 (State or other Jurisdiction                            (I.R.S. Employer
              of                                       Identification No.)
        Incorporation)

                     3960 Broadway, New York, New York 10032
                     ---------------------------------------
                    (Address of Principal Executive Offices)
                                   (Zip Code)


                                 (212) 781-5113
                                 --------------
              (Registrant's telephone number, including area code)

                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

<PAGE>

Item 8.01. Other Events.

On April 26, 2005, the Company issued a press release announcing the appointment
of Bernard Salick, M.D. as a new director to the Board. The full text of this
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K .

Item 9.01. Financial Statements and Exhibits.

      (c)   Exhibits

      99.1  Press Release issued by Nephros, Inc. on April 26, 2005 announcing
the appointment of Bernard Salick, M.D. to the Board of Directors.


<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date: April 26, 2005



                                    NEPHROS, INC.

                                    By: /s/ Marc L. Panoff
                                       ----------------------------
                                       Marc L. Panoff
                                       Chief Financial Officer (Principal
                                       Financial and Accounting Officer)


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>kl00464_ex99-1.txt
<DESCRIPTION>EXHIBIT 99.1 PRESS RELEASE
<TEXT>
                                                                    Exhibit 99.1

                       [GRAPHIC OMITTED][GRAPHIC OMITTED]

                                                           For Immediate Release
Contact:
Marc Pannoff                        Todd Fromer or Garth Russell
Chief Financial Officer             KCSA Worldwide
Nephros, Inc.                       212-896-1215 / 212-896-1250
Tel: 212-781-5113                   tfromer@kcsa.com / grussell@kcsa.com
                                    ----------------   -----------------

        Nephros Inc. Appoints Bernard Salick, M.D. To Board of Directors
                                      - - -

New York, April 26, 2005 - Nephros, Inc. (AMEX: NEP) announced today that
Bernard Salick, M.D., a nephrologist and healthcare entrepreneur, has joined the
Company's board of directors, increasing the number of board members to eight.

As the founder, former Chairman and CEO of Salick Health Care, Inc., Dr. Salick
developed long-term care concepts and solutions for patients with chronic and
catastrophic illness, including cancer and end-stage renal disease ("ESRD"). In
1997, Salick Health Care, Inc. was sold to Zeneca PLC (now Astra-Zeneca) for
approximately $500 million.

Currently Dr. Salick, as the Chairman and CEO of Salick Cardiovascular Centers,
LLC, is developing comprehensive cardiac centers to provide a broad range of
innovative services for the diagnosis and treatment of cardiovascular disease
including full diagnostic and treatment services (including those for
cerebrovascular, coronary artery, coronary heart and peripheral vascular
disease) on an outpatient basis.

Dr. Salick received his M.D. from the University of Southern California. He
completed his residency and training in nephrology as a NIH postdoctoral fellow
at Cedars-Sinai Medical Center and the University of California, Los Angeles.

"Dr. Salick is a great addition to our Board of Directors. He brings to Nephros
a wealth of knowledge as both a practicing physician and entrepreneur," stated
Norman Barta, CEO of Nephros. "Throughout his career he has shown an
extraordinary commitment to delivering advanced therapies in innovative and
cost-effective ways to patients with critical illnesses, including ESRD. We
share in his approach and look forward to his valuable contributions as we
continue to grow our family of patients worldwide."

Bernard Salick, M.D. commented, "I am pleased to join Nephros' Board of
Directors, and assist the Company in advancing cost effective state-of-the-art
treatment for patients suffering from ESRD. I look forward to offering my
expertise in supporting the Company's growth in the worldwide ESRD marketplace."

About Nephros Inc.
Nephros, Inc., headquartered in New York, is a medical device company developing
and marketing products designed to improve the quality of life for the End Stage
Renal

<PAGE>

Disease (ESRD) patient, while addressing the critical financial and clinical
needs of the care provider. ESRD is a disease state characterized by the
irreversible loss of kidney function. Nephros believes that its products are
designed to remove a range of harmful substances more effectively, and more
cost-effectively, than existing treatment methods; particularly with respect to
substances known collectively as "middle molecules," due to their molecular
weight, that have been found to contribute to such conditions as dialysis
related amyloidosis, carpal tunnel syndrome, degenerative bone disease and
ultimately, to mortality in the ESRD patient.

Forward Looking Statements
This news release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements, including statements regarding the efficacy and intended utilization
of Nephros's technologies under development, are not guarantees of future
performance, are based on certain assumptions and are subject to risks and
uncertainties, many of which are beyond the control of Nephros. Actual results
may differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risk that
potential products that appeared promising in early research or clinical trials
to Nephros do not demonstrate efficacy or safety in subsequent pre-clinical or
clinical trials, and the risk that Nephros will not obtain appropriate or
necessary governmental approvals to market products. More detailed information
about Nephros and the risk factors discussed above is set forth in Nephros'
filings with the Securities and Exchange Commission, including Nephros's Annual
Report on Form 10-KSB filed with the SEC on March 31, 2005. Investors and
security holders are urged to read such document free of charge at the
Commission's web site at www.sec.gov. Nephros does not undertake an obligation
to publicly update or revise its forward-looking statements as a result of new
information, future events or otherwise.

                                      # # #


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
